Jan Endell

MorphoSys (Germany) — Germany

Medicine · Health Sciences

13h-index868citations51works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(26), RNA Interference and Gene Delivery(16), Glycosylation and Glycoproteins Research(15), CAR-T cell therapy research(15), Multiple Myeloma Research and Treatments(9)

Publications51 total

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS
Blood·2023· 18 citedOpen Access
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
Frontiers in Immunology·2023· 5 citedOpen Access
Supplementary Table 1 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Materials and Methods from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 1 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 3 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 3 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Materials and Methods from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Data from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Table 1 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 2 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 1 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Data from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 4 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 4 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Supplementary Figure 2 from Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma
2023Open Access
Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
Cancer Immunology Immunotherapy·2022· 10 citedOpen Access
The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models
Transplantation and Cellular Therapy·2022· 1 cited
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study
Leukemia & lymphoma/Leukemia and lymphoma·2021· 23 citedOpen Access
The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models
Blood·2021· 4 cited
page 1 of 3Next →

Frequent Co-authors

Silke Wolterink(14), Gerhard Moldenhauer(14), Mina Fogel(14), Helena Kiefel(14), Marco Pfeifer(14), Sandra Lüttgau(14), Júlia Costa(14), Ulrich Moebius(14), Peter Altevogt(14), Rainer Boxhammer(14), Ricardo Gouveia(13), Stefan Steidl(11), Grzegorz S. Nowakowski(6), Luca Perabò(5), Michael Hallek(5), Reona Sakemura(5), Paulina Horvei(5), Mehrdad Hefazi(5), Michael W. Ruff(5), Christian Augsberger(5)